Guardant Health announced it intends to appeal yesterday’s verdict in the U.S. District Court for the District of Delaware related to intellectual property claims brought against Guardant by TwinStrand Biosciences, Inc. and University of Washington. Guardant remains confident that it did not infringe the asserted patents, and the company expects to file additional motions with the U.S. District Court for the District of Delaware and appeal to the U.S. Court of Appeals for the Federal Circuit.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on GH:
- Guardant Health upgraded to Outperform from Market Perform at Raymond James
- Guardant launches Shield blood-based screening test for CRC in South Korea
- Guardant Health price target lowered to $64 from $74 at Craig-Hallum
- Guardant Health raises FY23 revenue view to $553M-$556M, consensus $549.06M
- Guardant Health reports Q3 adjusted EPS (67c), consensus (95c)